Drugs like Ozempic and Wegovy may be helping researchers identify a brain region that plays a key role in cravings, according to ScienceDaily. The report says these GLP-1 agonists were originally developed to treat type 2 diabetes, but they also increase feelings of fullness and can lead to significant weight loss.
Researchers have also observed another effect: people taking GLP-1 drugs tend to drink less alcohol, and animal studies suggest the medicines may reduce use of cocaine, amphetamines, opiates and nicotine. That has led scientists to look more closely at how the brain processes reward and desire.
While much of the classic reward research has focused on dopamine-related areas such as the ventral tegmental area and nucleus accumbens, the article says those regions do not appear to have enough GLP-1 receptors to be the direct target. Instead, attention has shifted to the lateral septum, a brain region long associated with emotional regulation.
According to the report, the lateral septum gets input from the hippocampus and helps connect information about place, time and reward. It also contains many GLP-1 receptors, and emerging studies suggest activating those receptors can reduce food and alcohol consumption in mice.
The article says this line of research is reshaping ideas about how the brain handles reward and could eventually help explain the biology behind overeating, alcohol dependence and other addictive behaviors.
